Skip to main content
. 2021 Jan 22;12:2040620720987075. doi: 10.1177/2040620720987075

Figure 1.

Figure 1.

Response and safety data in clinical trials of subcutaneous and intravenous daratumumab.

d, dexamethasone; Dara-IV, intravenous daratumumab; Dara-SC, subcutaneous daratumumab; IRR, infusion-related reaction; M, melphalan; n, sample size; N/A, not applicable; ORR, overall response rate; P, prednisone; R, lenalidomide; V, bortezomib.